Literature DB >> 1532114

Frequency of adverse reactions to hepatitis B vaccine in 43,618 persons.

B J McMahon1, C Helminiak, R B Wainwright, L Bulkow, B A Trimble, K Wainwright.   

Abstract

PURPOSE: To determine the incidence of adverse reactions to hepatitis B plasma-derived vaccine. PATIENTS: Alaska natives (43,618) who received 101,360 doses of hepatitis B vaccine.
METHODS: All adverse reactions, excluding transient fever, myalgia, or soreness lasting less than 3 days, were reported. An intradermal skin test was developed to test purported adverse reactions. Records of the entire population were reviewed for Guillain-Barré syndrome (GBS).
SETTING: A statewide hepatitis B control program for Alaska natives.
RESULTS: Possible adverse reactions occurred in 39 persons. The most frequent adverse reactions were myalgia/arthralgia lasting longer than 3 days (14), followed by skin rashes (eight) and dizziness (seven). Skin tests were performed on 13 persons and were positive in five. Six of the persons with negative skin tests and eight persons who did not undergo skin testing received additional doses of vaccine without any adverse reactions. No increased incidence of GBS was found in the vaccinees.
CONCLUSION: Hepatitis B vaccine is safe and most adverse reactions are coincidental.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1532114     DOI: 10.1016/0002-9343(92)90073-k

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  20 in total

1.  Guillain Barre syndrome associated with hepatitis B vaccination.

Authors:  A Kakar; P K Sethi
Journal:  Indian J Pediatr       Date:  1997 Sep-Oct       Impact factor: 1.967

Review 2.  Guillain-Barré syndrome.

Authors:  U Seneviratne
Journal:  Postgrad Med J       Date:  2000-12       Impact factor: 2.401

3.  Vaccination and rheumatoid arthritis.

Authors:  J Sibilia; J F Maillefert
Journal:  Ann Rheum Dis       Date:  2002-07       Impact factor: 19.103

4.  A Longitudinal Hepatitis B Vaccine Cohort Demonstrates Long-lasting Hepatitis B Virus (HBV) Cellular Immunity Despite Loss of Antibody Against HBV Surface Antigen.

Authors:  Brenna C Simons; Philip R Spradling; Dana J T Bruden; Carolyn Zanis; Samantha Case; Tammy L Choromanski; Minjun Apodaca; Hazel D Brogdon; Gaelen Dwyer; Mary Snowball; Susan Negus; Michael G Bruce; Chihiro Morishima; Cindy Knall; Brian J McMahon
Journal:  J Infect Dis       Date:  2016-04-07       Impact factor: 5.226

Review 5.  Hepatitis B vaccine: a pharmacoeconomic evaluation of its use in the prevention of hepatitis B virus infection.

Authors:  S M Holliday; D Faulds
Journal:  Pharmacoeconomics       Date:  1994-02       Impact factor: 4.981

Review 6.  An update on drug-induced arthritis.

Authors:  Marwan H Adwan
Journal:  Rheumatol Int       Date:  2016-03-21       Impact factor: 2.631

Review 7.  Induced immunity against hepatitis B virus.

Authors:  Zeinab Nabil Ahmed Said; Kouka Saadeldin Abdelwahab
Journal:  World J Hepatol       Date:  2015-06-28

8.  Low prevalence of hepatitis B virus infection in patients with systemic lupus erythematosus in southern China.

Authors:  Jijun Zhao; Minli Qiu; Meirong Li; Caisheng Lu; Jieruo Gu
Journal:  Rheumatol Int       Date:  2009-10-14       Impact factor: 2.631

Review 9.  Chronic hepatitis B in 2014: great therapeutic progress, large diagnostic deficit.

Authors:  Claus Niederau
Journal:  World J Gastroenterol       Date:  2014-09-07       Impact factor: 5.742

10.  Improving hepatitis B vaccine efficacy in end-stage renal diseases patients and role of adjuvants.

Authors:  Mohammad Hossein Somi; Babak Hajipour
Journal:  ISRN Gastroenterol       Date:  2012-09-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.